

Atty. Dkt. No.
037003-0280609Client Ref.
2000-30-0154A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: GRILLO-LOPEZ

Appln. No.: 09/840,872

Filing Date: September 12, 2002

Date: May 12, 2004

Page 1 of 4

Examiner: Gary B. Nickol

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
GR						
HR						
IR						
JR						

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

KR	Blaney SM et al., "Neoplastic meningitis: diagnosis and treatment considerations," <i>Med Oncol</i> , 2000, 17: 151-162.
LR	Cokgor I et al., "Current options for the treatment of neoplastic meningitis," <i>J Neurooncol</i> , 2002, 60: 79-88.
MR	Harjunpaa A et al., "Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma," <i>Leuk Lymphoma</i> , 2001, 42: 731-738.
NR	Pels H et al., "Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature," <i>Onkologie</i> , 2003, 26: 351-354.
OR	Rubenstein JL et al., "Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment," <i>Blood</i> , 2003, 101: 466-468.
PR	
QR	
RR	
SR	
TR	
UR	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.